Piramal Pharma gains 10% after 70+ approvals in FY26

Stock jumps after compliance update

Shares of Piramal Pharma Ltd. rose over 10% on Tuesday after the company said it received more than 70 approvals from regulatory agencies across its global network in the past fiscal year. The stock moved sharply higher in early trade, reflecting how sensitive pharma names can be to compliance and inspection-readiness milestones. At around 10:00 am, the scrip was up as much as 10.69% at Rs 174.80. In the Nifty Pharma pack, 19 out of 20 constituents were trading in the green, with Piramal Pharma leading gains at about 9.8% near ₹174.

What the company highlighted behind the approvals

Piramal Pharma attributed the approvals outcome to its quality framework. The company said the framework is built around governance, workforce training, process standardisation, and digital systems designed to improve compliance and inspection readiness. It also said it uses predictive tools to assess site readiness, and tailored quality systems to reduce errors and improve efficiency. The company flagged its RESOLVE programme, which focuses on right-first-time execution in manufacturing and quality control operations. Under this programme, it highlighted measures such as batch record reviews and increased shopfloor oversight. Piramal Pharma also said it has introduced training programmes focused on audit readiness and regulatory engagement.

Why pharma stocks have been in focus

Analysts linked the broader strength in pharma stocks to multiple overlapping drivers. They cited defensive buying and strong earnings visibility as key supports, along with export tailwinds and sector rotation into pharmaceuticals. Ponmudi R, CEO at Enrich Money, said that the improving outlook for Indian pharmaceutical exporters is attracting buyers. He also pointed to increasing opportunities in specialty drugs, CDMO, biosimilars, and complex generics as confidence builders. In his view, investors are beginning to recognise Indian pharma’s gradual shift from a pure generics narrative toward innovation-led growth.

Other trading signals investors tracked

The stock has also been in the middle of several short-term moves that investors have been watching. One data point noted in the market was a forecast that earnings are expected to grow 84.48% per year. Separately, the stock was noted as being out of F&O “from today,” a change that can alter liquidity and trading behaviour for some participants. Market commentary also reflected mixed sentiment, with some noting that there was “nothing great in results” and that a stronger quarter was still awaited. At the same time, the theme that “all CDMO stocks [are] performing well” has been part of the broader rotation.

Early May rally: institutional interest and heavy volume

Piramal Pharma’s trading in early May showed sharp moves across sessions. The stock rebounded on 6 May, gaining 3.32% to close at Rs.165.10. Its most notable move came on 7 May, when the stock surged 11.36% to close at Rs.183.85. The same update noted an intraday high of Rs.175.70 earlier in the session and an 8.42% intraday gain.

The 7 May move significantly outpaced the Pharmaceuticals & Biotechnology sector and the broader Sensex, which rose 0.34% that day. On a weekly basis, Piramal Pharma’s 12.13% gain was cited as well ahead of the Sensex’s 1.25%, with the rally on 7 May linked to exceptional volume and institutional interest. However, the one-year performance was also described as negative at -15.70%, positioning the rally as a rebound within a longer downtrend.

CDMO contract update: Botanix adds Piramal as supplier

In another development, Piramal Pharma secured a new commercial contract for its overseas unit. Botanix Pharmaceuticals announced that it onboarded Piramal Pharma as a secondary API supplier for Sofdra (sofpironium bromide). Manufacturing is to be carried out at Piramal’s Riverview facility, with scale-up expected from FY28. A brokerage estimate put peak revenue potential from this opportunity at $15 million to $10 million.

Q3FY26 loss, but the stock rose

Piramal Pharma shares also moved higher on a separate day even after the company reported a net loss of ₹136 crore in Q3FY26. The stock rose about 4% and touched an intraday high of around ₹163 versus the previous close of ₹154.25. Market participants highlighted that investors looked past the headline loss, focusing instead on one-time exceptional costs, sequential improvement in revenue and EBITDA, early recovery signals in the CDMO business, and strong growth momentum in consumer healthcare. The commentary also pointed to labour law-related costs and a customer settlement as one-off exceptional items, rather than a structural deterioration in the business.

Key numbers at a glance

What to watch next

The immediate trigger for Tuesday’s move was the company’s update on approvals and its description of systems intended to improve compliance and inspection readiness. In parallel, the sector’s bid has been supported by analyst commentary around export tailwinds, earnings visibility, and rotation into pharma.

From here, investors are likely to track follow-through on manufacturing and quality-control execution, additional regulatory outcomes across Piramal’s network, and progress on the Riverview facility scale-up timeline expected from FY28. Market attention is also likely to remain on CDMO recovery indicators and how the business mix evolves alongside consumer healthcare momentum.